Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Share-based Compensation: 2010-2025

Historic Share-based Compensation for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $19.1 million.

  • Arrowhead Pharmaceuticals' Share-based Compensation fell 1.99% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.4 million, marking a year-over-year decrease of 14.33%. This contributed to the annual value of $63.4 million for FY2025, which is 14.33% down from last year.
  • As of Q3 2025, Arrowhead Pharmaceuticals' Share-based Compensation stood at $19.1 million, which was up 46.34% from $13.0 million recorded in Q2 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Share-based Compensation ranged from a high of $34.6 million in Q3 2021 and a low of $13.0 million during Q2 2025.
  • In the last 3 years, Arrowhead Pharmaceuticals' Share-based Compensation had a median value of $18.2 million in 2023 and averaged $17.8 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' Share-based Compensation spiked by 200.88% in 2021 and then slumped by 40.26% in 2023.
  • Arrowhead Pharmaceuticals' Share-based Compensation (Quarterly) stood at $24.5 million in 2021, then declined by 20.87% to $19.4 million in 2022, then rose by 1.57% to $19.7 million in 2023, then dropped by 22.77% to $15.2 million in 2024, then declined by 1.99% to $19.1 million in 2025.
  • Its Share-based Compensation was $19.1 million in Q3 2025, compared to $13.0 million in Q2 2025 and $16.0 million in Q1 2025.